Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea

NCT05132101 · clinicaltrials.gov ↗

COMPLETED

Status

2758

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Patients who received Palbociclib as first line therapy in MBC setting

Sponsor

Pfizer